Important Safety Information On Yescarta (axicabtagene Ciloleucel) And The Risk Of Cerebral Edema In Primary Mediastinal B Cell Lymphoma (pmbcl)

Yescarta, a cancer treatment used for primary mediastinal B cell lymphoma, is being recalled in Canada due to new safety information about a risk of cerebral edema (swelling in the brain). The recall affects the intravenous suspension form of the drug that has been distributed across Canada. Patients currently using or considering this treatment should contact their healthcare provider about this safety update.

Product

Yescarta (axicabtagene ciloleucel) Suspension for Intravenous Infusion

Reason

New safety information

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2025-12-10

Status

Ongoing

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/07bf8b8f-969a-4244-9636-12b76a5d35b1